Erschienen in:
Current Neuropharmacology, 21 (2023) 3, Seite 708-714
Sprache:
Englisch
DOI:
10.2174/1570159x21666221117152249
ISSN:
1570-159X
Entstehung:
Anmerkungen:
Beschreibung:
Background:Status epilepticus (SE) is a serious neurological disease that manifests as prolongedseizures that last more than 5 minutes and between such episodes, patients do not regain consciousness.It can result in cognitive defects, brain damage, or even death. It is commonly known thatone of the causes can be an inflammatory process, but here we will focus on inflammation as a resultof new onset refractory status epilepticus and, related to this, new promising forms of SE treatment.Particular emphasis has been focused on new-onset refractory status epilepticus (NORSE).Methods:Based on public research databases, drugs with anti-inflammatory activity – commonly usedin different spheres of medicine – have been reviewed as potentially treating status epilepticus.Results:There is seizable clinical research suggesting that drugs that decrease inflammatory processesmight be effective in terminating status epilepticus.Conclusion:There is growing evidence showing that adding anti-inflammatory drugs to basic antiepileptictreatment enhances the efficiency of the therapeutic process, with special potential in NORSEcases.